SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

REGOLI, Domenico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.038
AS - Asia 4.214
EU - Europa 3.072
SA - Sud America 618
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 18.007
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.865
SG - Singapore 1.722
CN - Cina 1.309
DE - Germania 840
UA - Ucraina 571
BR - Brasile 518
IT - Italia 402
GB - Regno Unito 372
HK - Hong Kong 359
TR - Turchia 356
FI - Finlandia 332
VN - Vietnam 239
RU - Federazione Russa 137
SE - Svezia 130
CA - Canada 97
FR - Francia 82
MX - Messico 56
IN - India 55
PL - Polonia 44
BE - Belgio 41
JP - Giappone 40
AR - Argentina 35
ZA - Sudafrica 30
LT - Lituania 28
NL - Olanda 27
BD - Bangladesh 26
ES - Italia 26
ID - Indonesia 19
EC - Ecuador 18
IQ - Iraq 18
CO - Colombia 11
UZ - Uzbekistan 10
AE - Emirati Arabi Uniti 9
CL - Cile 9
MA - Marocco 8
PK - Pakistan 8
CZ - Repubblica Ceca 7
IR - Iran 7
PE - Perù 7
PY - Paraguay 7
UY - Uruguay 7
AT - Austria 6
BG - Bulgaria 6
VE - Venezuela 6
DO - Repubblica Dominicana 5
LB - Libano 5
NP - Nepal 5
SA - Arabia Saudita 5
EG - Egitto 4
IL - Israele 4
SN - Senegal 4
AL - Albania 3
AU - Australia 3
BH - Bahrain 3
HR - Croazia 3
JM - Giamaica 3
JO - Giordania 3
KE - Kenya 3
PA - Panama 3
TN - Tunisia 3
CR - Costa Rica 2
DK - Danimarca 2
EU - Europa 2
GR - Grecia 2
HN - Honduras 2
IE - Irlanda 2
KR - Corea 2
MY - Malesia 2
RO - Romania 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
KH - Cambogia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
NE - Niger 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 18.007
Salva come PNG Salva come JPEG
Città #
Fairfield 1.109
Woodbridge 1.076
Singapore 1.075
Ashburn 969
Houston 664
Jacksonville 614
Ann Arbor 559
Chandler 519
Beijing 454
Santa Clara 414
Seattle 409
Wilmington 392
Hong Kong 358
Cambridge 352
Munich 342
Izmir 193
Nanjing 178
Los Angeles 162
New York 148
Helsinki 138
Milan 132
Dallas 121
Princeton 118
San Diego 109
Boardman 100
Ho Chi Minh City 84
Shanghai 75
Turku 71
São Paulo 58
Nanchang 57
Dearborn 56
Hanoi 56
Shenyang 51
Falls Church 44
London 43
Brussels 40
Orem 40
Tokyo 39
Brooklyn 35
Denver 35
Mexico City 34
Bremen 33
Falkenstein 33
Hefei 33
Hebei 32
Warsaw 32
Ferrara 31
Buffalo 30
Frankfurt am Main 30
Auburn Hills 29
Jiaxing 29
Tianjin 29
Changsha 28
Mountain View 27
San Mateo 27
Jinan 26
Montreal 25
Toronto 24
Johannesburg 23
Phoenix 23
Mcallen 22
Norwalk 22
Atlanta 21
Philadelphia 21
Moscow 20
Redwood City 20
Addison 19
Boston 19
Poplar 19
Chicago 18
Kunming 18
Rio de Janeiro 18
Zhengzhou 18
Montréal 17
San Francisco 17
Stockholm 16
Bexley 15
Manchester 15
Chennai 13
The Dalles 13
Indiana 12
Ningbo 12
Tappahannock 12
Ankara 11
Belo Horizonte 11
Mumbai 11
Des Moines 10
Guangzhou 10
Biên Hòa 9
Curitiba 9
Tashkent 9
Wroclaw 9
Augusta 8
Bologna 8
Carapicuíba 8
Charlotte 8
Columbus 8
Da Nang 8
Querétaro 8
Baghdad 7
Totale 12.616
Salva come PNG Salva come JPEG
Nome #
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 347
AGONISTI PIENI E PARZIALI ED ANTAGONISTI DEL RECETTORE PER NOCICETTINA/ORFANINA FQ AD ELEVATA POTENZA” 292
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8 ,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vivo studies 277
Characterization of FR 172357, a new non-peptide bradykinin B2 receptor antagonist, in human, pig and rabbit preparations 244
A new selective antagonist of the nociceptin receptor 236
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 235
Human vascular kinin receptors of the B-2 type characterized by radioligand binding 222
A new ligand for the urotensin II receptor 218
Kinin B-1 and B-2 receptors in pig vessels: characterization of two monoreceptor systems 216
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor 212
Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2 206
N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands 206
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide 205
Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist 201
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 200
Effects of vasoactive agents in healthy and diseased human saphenous veins 195
Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide 193
Ala scan analogues of HOE 140. Synthesis and biological activities 190
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 189
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 188
UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor 188
Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences 187
Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: In vitro and in vivo studies 186
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ; Behavioral and electrophysiological studies in mice 186
[Nphe(1)]nociceptin-(1-13)NH2 selectively antagonizes nociceptin effects in the rabbit isolated ileum 185
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist 185
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 183
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 181
In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist Netupitant. 180
Pharmacological characterization of nociceptin receptor: an in vitro study 179
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents 178
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 178
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist 177
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay 176
Pharmacological characterisation of novel kinin B2 receptor ligands 175
B1 and B2 kinin receptors in various species 174
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 174
Characterization of [Nphe(1)]nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist 171
[Arg(14), Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies 170
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with C alpha,alpha-dialkylated amino acids 169
Structure-activity study at positions 3 and 4 of human neuropeptide S. 168
Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice 167
Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice 166
Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy 166
Pharmacology of [Tyr(1)]nociceptin analogs: receptor binding and bioassay studies 165
Autoradiographic analysis of rat brain kinin B-1 and B-2 receptors: Normal distribution and alterations induced by epilepsy 165
Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus 165
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies 164
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 164
Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11) 161
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5 159
The nociceptin/orphanin FQ receptor antagonist, [Nphe(1)]NC(1-13)NH2, potentiates morphine analgesia 159
Anxiolytic and antidepressant-like activities of UFP-512, a novel selective delta opiold receptor agonist 155
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 155
Bradykinin receptors and receptor ligands (with special emphasis on vascular receptors) 154
Characterization of the human vascular kinin B2 receptor by binding assays. 153
Studies on the antinociceptive effect of [Nphe(1)]nociceptin(1-13)NH2 in mice 152
Structure-activity relationship study on Tyr9 of urotensin-II(4-11): Identification of a partial agonist of the UT receptor 152
Angiotensin II-induced increase of T-type Ca2+ current and decrease of L-type Ca2+ current in heart cells 152
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors 152
Pharmacological profile of hemokinin 1: a novel member of the tachykinin family 148
Structure-activity relationship study on human urotensin II 148
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen(5), DTrp(7), Dab(8)] urotensin II(4-11) (UFP-803) 146
Characterization of endothelin receptors in the human umbilical artery and vein 145
Nociceptin/orphanin FQ receptor ligands 145
Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats 143
The mouse vas deferens: A pharmacological preparation sensitive to nociceptin 143
Nociceptin receptor binding in mouse forebrain membranes: Thermodynamic characteristics and structure activity relationships 142
Pharmacology of the Kallikrein-Kinin system 142
Structure-activity studies on neuropeptide S - Identification of the amino acid residues crucial for receptor activation 141
Bradykinin B2 receptors increase hippocampal excitability and susceptibility to seizures in mice 140
ANALOGHI DERMASEPTINICI AD ATTIVITA’ ANTIMICROBICA 140
ANTAGONISTI DEL RECETTORE UT E LORO USI TERAPEUTICI 139
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor 138
Receptors for kinins in the human isolated umbilical vein 137
Effects of intrathecal nocistatin on the flexor reflex and its interaction with orphanin FQ nociceptin 137
In vitro pharmacological profile of peptide III-BTD: A novel ligand for nociceptin/orphanin FQ and opioid receptors 136
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor 136
In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist 136
Pharmacology of nociceptin and its receptor: a novel therapeutic target 134
In vitro characterization of FR 190997, the first non peptide B2 receptor agonist receptor binding and bioassay in the human umbilical vein 130
Effects of Ro 64-6198 it nociceptin/orphanin FQ-sensitive isolated tissues 130
Nociceptin/orphanin FQ inhibits electrically induced contractions of the human bronchus via NOP receptor activation 129
Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors 128
Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH2: Identification of highly potent agonists of the nociceptin/orphanin FQ receptor 128
Angiotensin II induced increase in frequency of cytosolic and nuclear calcium waves of heart cells via activation of AT(1) and AT(2) receptors 127
FR 173657: a new, potent, nonpeptide kinin B2 receptor antagonist. An in vitro study 125
Contractile activity of endothelins and their precursors in human umbilical artery and vein: identification of distinct endothelin-converting enzyme activities 123
Pharmacology of [tyr1]nociceptin analogs: receptor binding and bioassay studies 120
Receptor binding profile of novel nociceptin/orphanin FQ receptor ligands in mouse brain membranes. 118
Further studies on nociceptin/orphanin FQ related peptides: discovery of a new chemical template with antagonist activity on the OP4 receptor. 115
Further studies on nociceptin related peptides: discovery of new molecules with antagonist activity on the nociceptin receptor 115
Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test 113
Pharmacological characterisation of [(pX)Phe(4)]nociceptin(1-13)amide analogues - 1. In vitro studies 106
Expression and biological activity of B1 bradykinin receptors in two experimental models of epilepsy 106
Pharmacological characterization of the nociceptin receptors in the mouse: receptor binding, bioassay and behavioral studies 104
Highly potent full and partial agonists and anatagonists of the nociceptin/orphanin FQ receptor 103
null 99
null 98
Identificazione di un antagonista del recettore UT 96
Totale 16.377
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.047
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021853 0 0 0 0 0 159 53 177 30 166 204 64
2021/20221.308 44 137 96 98 87 56 73 72 57 94 123 371
2022/20231.332 125 50 62 168 224 176 112 100 196 7 68 44
2023/2024631 76 78 37 16 39 133 21 42 13 12 14 150
2024/20252.785 54 51 206 106 337 315 133 177 397 244 405 360
2025/20264.290 827 316 632 996 1.142 377 0 0 0 0 0 0
Totale 18.112